echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Pfizer's tick-borne encephalitis vaccine approved in the U.S. for active immunization of people ≥ 1 year old

    Pfizer's tick-borne encephalitis vaccine approved in the U.S. for active immunization of people ≥ 1 year old

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pfizer recently announced that the U.


    TBE is a viral infection of the brain and spine that is transmitted to humans through the bite of an infected tick


    Although TBE is not endemic in the United States so far, it has been found in more than 35 countries in Europe and Asia


    Pfizer's TBE vaccine has been used outside the United States for more than 45 years.


    In clinical trials, the safety and immunogenicity of TICOVAC were evaluated in 2 age groups (1-15 years old, >16 years old)


    Original source: US FDA Approves TICOVAC™, Pfizer's Tick-Borne Encephalitis (TBE) Vaccine

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.